Tango Therapeutics Inc
NASDAQ:TNGX

Watchlist Manager
Tango Therapeutics Inc Logo
Tango Therapeutics Inc
NASDAQ:TNGX
Watchlist
Price: 5.7 USD 4.97%
Market Cap: 617.8m USD

Wall Street
Price Targets

TNGX Price Targets Summary
Tango Therapeutics Inc

Wall Street analysts forecast TNGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TNGX is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 13.65 USD.

Lowest
Price Target
8.08 USD
42% Upside
Average
Price Target
10.2 USD
79% Upside
Highest
Price Target
13.65 USD
139% Upside
Tango Therapeutics Inc Competitors:
Price Targets
BONEX
Bonesupport Holding AB
51% Upside
XGN
Exagen Inc
15% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
32% Upside
2696
Shanghai Henlius Biotech Inc
36% Downside
ASMB
Assembly Biosciences Inc
79% Upside
SPRY
ARS Pharmaceuticals Inc
80% Upside
HUMA
Humacyte Inc
268% Upside
ADMA
ADMA Biologics Inc
69% Upside

Revenue
Forecast

Revenue Estimate
Tango Therapeutics Inc

The compound annual growth rate of Tango Therapeutics Inc's revenue for the next 3 years is -14%.

N/A
Past Growth
-14%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Tango Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Tango Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TNGX's stock price target?
Price Target
10.2 USD

According to Wall Street analysts, the average 1-year price target for TNGX is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 13.65 USD.

What is Tango Therapeutics Inc's Revenue forecast?
Projected CAGR
-14%

The compound annual growth rate of Tango Therapeutics Inc's revenue for the next 3 years is -14%.

Back to Top